APT Medical (688617) Q3 2026 earnings summary

Executive summary

• Q3 revenue rose 27.24% YoY to RMB 831.7m; attributable net income increased 41.76% to RMB 280.9m, supported by sales growth, stronger product profitability and cost controls.

• 9M revenue increased 26.27% YoY to RMB 2.358bn and attributable net income rose 31.27% to RMB 818.2m.

Financial highlights

• Q3 total profit was RMB 329.2m, up 45.39% YoY; net income attributable to shareholders excluding non-recurring items was RMB 277.4m, up 44.95%.

• 9M total profit reached RMB 932.4m, up 32.11%; adjusted attributable net income was RMB 806.2m, up 33.87%.

• 9M operating cash flow increased 40.26% YoY to RMB 948.2m; higher cash receipts from sales of goods and services were cited as the main driver.

Key financial ratios and metrics

• Basic EPS was RMB 2.05 in Q3, up 45.39% YoY, and RMB 5.87 for 9M, up 32.81%.

• 9M weighted average ROE was 25.95%, up 3.54 percentage points YoY; diluted EPS was RMB 5.87 versus RMB 4.41 in 9M 2025.

• 9M R&D spending was RMB 315.2m, up 23.56%; R&D was 13.37% of revenue, down 0.29 percentage points YoY.